BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces positive interim results from a human pilot study (the “Study”) currently underway evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1") drug semaglutide available commercially in the branded product Rybelsus®.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 1:00 p.m. ET.

HiberCell, a clinical-stage biotechnology company dedicated to addressing mechanisms of treatment resistance, cancer relapse, and metastasis, today announced the successful completion of its Phase 1 study of the novel PERK inhibitor, HC-5404, in solid tumors along with two pre-clinical publications in one of the leading journals of AACR, Clinical Cancer Research (CCR).

GE HealthCare announced the release of a new, all-in-one platform of artificial intelligence apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite*.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Naturevan Nutrition Ltd.

The global vaccine contract manufacturing market size was valued at USD 3.1 billion in 2022 and is projected to surpass around USD 8.92 billion by 2032, expanding at a remarkable CAGR of 11.2% from 2023 to 2032.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (“Aires” or the “Company”), a pioneer in EMF modulation technology, is pleased to announce that the Company has granted 10,000 stock options (each an “Option”) to an arm’s length consultant pursuant to option agreement and the terms and conditions of the omnibus long-term incentive plan of the Company.

Regulatory News: Median Technologies is proud to have been chosen to join the ETIncelles scheme, an initiative created by the President of the French Republic, which aims to help 500 high growth potential SMEs in their transition to becoming an ETI, by 2027.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American digital health platform and provider of remote patient monitoring (RPM) solutions, is pleased to report results for the 3 months and 9 months ending September 30, 2023.